At Vivosel, we supply GMP-grade raw materials and establish a high-quality, self-sustaining ecosystem that supports the production of Advanced Therapy Medicinal Products (ATMPs). From stem cell lines to delivery vectors, our infrastructure ensures safety, scalability, and global readiness.
Vivosel produces GMP-compliant mesenchymal stem cells and engineered exosomes derived from ethically sourced umbilical cord tissue. These are used in regenerative medicine, immune modulation, and aesthetic applications.
Our gene editing platforms include viral and non-viral delivery systems (e.g., lentiviral) developed under GMP conditions. We support ex vivo editing for customized cell therapy development.
We develop and maintain master and working cell banks to ensure a stable, traceable source of therapeutic cells for clinical and research use. All processes are conducted in cleanroom suites under EMA- and FDA-aligned standards.